Overview

Study of AFP464 +/- Faslodex in ER + Breast Cancer

Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
0
Participant gender:
Female
Summary
AFP464 is an investigational agent which may be effective in the treatment of cancer. The purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer patients.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tigris Pharmaceuticals
Treatments:
Estradiol
Fulvestrant
Criteria
Inclusion Criteria:

- proven breast cancer, ER+ status; progression on an aromatase inhibitor; measurable
disease or evaluable disease with serum CA27.29>=50 U/mL; adequate bone marrow, liver
and renal function; DLco grade 0 or 1.

Exclusion Criteria:

- HER2 positive, thoracic radiotherapy or symptomatic pulmonary disease, brain
metastases,